You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: NIADESCRIPTION (provided by applicant): A strong unmet need exists to develop new treatments for anemias associated with chronic disease states, collectively referred to as anemia of chronic inflammation (ACI). ACI is highly prevalent in the U.S. and makes alarge contribution to public morbidity and mortality. Despite billions of dollars spent annually to treat ACI patients, current therapies lack e ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Therapeutic for Alzheimer' Disease
SBC: CoPlex Therapeutics, LLC Topic: NIADESCRIPTION (provided by applicant): Traditional approaches to drug development for Alzheimer's disease are becoming increasingly expensive and in many cases disappointingly unsuccessful. Based on preliminary in vitro and in vivo studies we have identifieda novel lactam derivative of the commonly prescribed 1,4 dihydropyridine calcium channel blocker nifedipine (1-acetyl-2,4- dimethylbenzo[c] ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Long-Term Broad-Spectrum Prevention of Implant-Related Infections
SBC: Biomedical Development Corporation Topic: NIADESCRIPTION (provided by applicant): Deep wound infection following total joint arthroplasty is a devastating complication for physician and patient, a leading cause of morbidity, and a significant economic burden to the healthcare system. With an aging population and increased life expectancies, the number of arthroplasties is expected to rise dramatically over the next 20 years. The growing numb ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Delayed Tolerance Induction in Living Related Donor Renal Transplant Recipients
SBC: REGENEREX, LLC Topic: NIAIDDESCRIPTION (provided by applicant): We have developed a protocol that reproducibly induces transplantation tolerance in individuals undergoing a living related donor kidney transplant. Three subjects have been off all immunosuppression for 10 months, 2 months, and 1 month respectively and have remained chimeric with stable renal function. Two additional chimeric subjects are in various stages of ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Development of a Plasma Biomarker of Alzheimer's Disease
SBC: SCOUT DIAGNOSTICS Topic: NIEHSDESCRIPTION (provided by applicant): The major barriers to preventing or treating Alzheimer's disease (AD) are its unknown pathogenesis/etiology and the lack of an objective, sensitive and specific biomarker of the disease, particularly at the early stageswhen therapeutic interventions would likely have the greatest efficacy. The basic hypothesis of this application is that plasma levels of a ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial DNA repair agents for acute lung injury
SBC: EXSCIEN CORPORATION Topic: NHLBIDESCRIPTION (provided by applicant): Drug development for acute lung injury (ALI) has been marred by unfulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the history of therapeutic strategies directed at inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Transdermal Naltrexone for Opiate Addiction and Alcoholism
SBC: ALLTRANZ, INC. Topic: NIDADESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...
STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health -
Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi
SBC: CytoInformatics LLC Topic: NIAMSDESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
human Microvessel Culture System (hMCS)
SBC: ANGIOMICS, INC. Topic: NHLBIDESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Epitaxial GaN on flexible metal tapes for low-cost transistor devices
SBC: IBEAM MATERIALS, INC. Topic: 1GaN-based devices are the basis of a variety of modern electronics applications, especially in optoelectronics and high-frequency / high-power electronics. These devices are based on epitaxial films grown on single-crystal wafers. The single-crystal wafer substrates are limiting because of their size, expense, mechanical properties and availability. If one could make GaN-based devices over large a ...
STTR Phase I 2013 Department of EnergyARPA-E